Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start

This article was originally published in The Pink Sheet Daily

Executive Summary

Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.

Advertisement

Related Content

EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
The Orphan Drug Boom: Gold Rush Or Flash In The Pan?
AdventRx Showing Signs Of Life With SynthRx Acquisition, NDA For Exelbine
Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel